^
    Back
    Association details:
    Biomarker:RUNX1 mutation
    Cancer:Myelodysplastic Syndrome
    Drug:azacitidine (DNMT inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Ann Hematol
    Title:

    Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine

    Excerpt:
    Patients with SF3B1 mutations showed a better response to AZA (68% vs. 35% responders, P = 0.008). In contrast, subjects with mutations in transcription factors (RUNX1, SETBP1, NPM1) showed a worse response (20% vs. 47% responders, P = 0.014).
    DOI:
    10.1007/s00277-020-03932-8.